BioSpace News Archive

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced data presented during the European Association for the Study of the Liver (EASL) Congress 2023, taking place in Vienna, Austria.

Kala Pharmaceuticals, Inc., announced that the Company granted non-statutory stock options and restricted stock units to new employees as inducement awards outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635.

Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher.

Rosalind Franklin University of Medicine and Science (RFU) has completed the final buildout of 14,000 square feet of wet lab space for bioscience-industry occupancy in its Innovation and Research Park (IRP).

TRxADE HEALTH, Inc., a pharmaceutical exchange platform, announced a correction to its press release issued on Friday, June 23, 2023, 8:05 U.S. Eastern Time, entitled “Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform”.

Enochian BioSciences Inc. wishes to advise that its 2023 Annual Stockholder Meeting, which was scheduled to be held yesterday, June 22, 2023 at 12:00 p.m. Eastern Time, was convened and adjourned, without any business being conducted, due to the lack of the required quorum.

Boehringer Ingelheim and Zealand Pharma A/S announced additional data demonstrating superior efficacy with survodutide versus placebo in people with overweight or obesity without type 2 diabetes after 46 weeks of treatment.1 The findings were presented at the 2023 American Diabetes Association’s 83rd Scientific Sessions in San Diego, CA, U.S.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved LITFULO™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata.

Findings from SURMOUNT-2, a study of tirzepatide in participants with type 2 diabetes who have obesity were announced, demonstrating more weight loss in individuals with diabetes than any other medication to date.

Dexcom, Inc. announced its strategy to bring Dexcom glucose sensing technology to millions more people around the globe and new Dexcom CGM research featured at the 83rd Scientific Sessions of the American Diabetes Association being held June 23-26 in San Diego.